Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Susan M. Edgerton

TitleSenior Instructor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-Pathology
Phone303/724-3751

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Wellberg EA, Checkley LA, Giles ED, Johnson SJ, Oljira R, Wahdan-Alaswad R, Foright RM, Dooley G, Edgerton SM, Jindal S, Johnson GC, Richer JK, Kabos P, Thor AD, Schedin P, MacLean PS, Anderson SM. The Androgen Receptor Supports Tumor Progression After the Loss of Ovarian Function in a Preclinical Model of Obesity and Breast Cancer. Horm Cancer. 2017 Jul 24. PMID: 28741260.
      View in: PubMed
    2. Checkley LA, Rudolph MC, Wellberg EA, Giles ED, Wahdan-Alaswad RS, Houck JA, Edgerton SM, Thor AD, Schedin P, Anderson SM, MacLean PS. Metformin Accumulation Correlates with Organic Cation Transporter 2 Protein Expression and Predicts Mammary Tumor Regression In Vivo. Cancer Prev Res (Phila). 2017 Mar; 10(3):198-207. PMID: 28154203.
      View in: PubMed
    3. Gari HH, Gearheart CM, Fosmire S, DeGala GD, Fan Z, Torkko KC, Edgerton SM, Lucia MS, Ray R, Thor AD, Porter CC, Lambert JR. Genome-wide functional genetic screen with the anticancer agent AMPI-109 identifies PRL-3 as an oncogenic driver in triple-negative breast cancers. Oncotarget. 2016 Mar 29; 7(13):15757-71. PMID: 26909599; PMCID: PMC4941275.
    4. Lyu H, Yang XH, Edgerton SM, Thor AD, Wu X, He Z, Liu B. The erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cells. Oncotarget. 2016 Jan 19; 7(3):2921-35. PMID: 26621843; PMCID: PMC4823081.
    5. Wahdan-Alaswad R, Harrell JC, Fan Z, Edgerton SM, Liu B, Thor AD. Metformin attenuates transforming growth factor beta (TGF-ß) mediated oncogenesis in mesenchymal stem-like/claudin-low triple negative breast cancer. Cell Cycle. 2016; 15(8):1046-59. PMID: 26919310; PMCID: PMC4889288 [Available on 02/26/17].
    6. Lyu H, Huang J, Edgerton SM, Thor AD, He Z, Liu B. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells. Int J Clin Exp Pathol. 2015; 8(6):6143-56. PMID: 26261492; PMCID: PMC4525826.
    7. Wahdan-Alaswad RS, Cochrane DR, Spoelstra NS, Howe EN, Edgerton SM, Anderson SM, Thor AD, Richer JK. Metformin-induced killing of triple-negative breast cancer cells is mediated by reduction in fatty acid synthase via miRNA-193b. Horm Cancer. 2014 Dec; 5(6):374-89. PMID: 25213330; PMCID: PMC4570735.
    8. Jindal S, Gao D, Bell P, Albrektsen G, Edgerton SM, Ambrosone CB, Thor AD, Borges VF, Schedin P. Postpartum breast involution reveals regression of secretory lobules mediated by tissue-remodeling. Breast Cancer Res. 2014 Mar 28; 16(2):R31. PMID: 24678808; PMCID: PMC4053254.
    9. Cochrane DR, Bernales S, Jacobsen BM, Cittelly DM, Howe EN, D'Amato NC, Spoelstra NS, Edgerton SM, Jean A, Guerrero J, Gómez F, Medicherla S, Alfaro IE, McCullagh E, Jedlicka P, Torkko KC, Thor AD, Elias AD, Protter AA, Richer JK. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Res. 2014 Jan 22; 16(1):R7. PMID: 24451109; PMCID: PMC3978822.
    10. Zhu P, Davis M, Blackwelder AJ, Bachman N, Liu B, Edgerton S, Williams LL, Thor AD, Yang X. Metformin selectively targets tumor-initiating cells in ErbB2-overexpressing breast cancer models. Cancer Prev Res (Phila). 2014 Feb; 7(2):199-210. PMID: 24322659; PMCID: PMC4497590.
    11. Wahdan-Alaswad R, Fan Z, Edgerton SM, Liu B, Deng XS, Arnadottir SS, Richer JK, Anderson SM, Thor AD. Glucose promotes breast cancer aggression and reduces metformin efficacy. Cell Cycle. 2013 Dec 15; 12(24):3759-69. PMID: 24107633; PMCID: PMC3905068.
    12. Callihan EB, Gao D, Jindal S, Lyons TR, Manthey E, Edgerton S, Urquhart A, Schedin P, Borges VF. Postpartum diagnosis demonstrates a high risk for metastasis and merits an expanded definition of pregnancy-associated breast cancer. Breast Cancer Res Treat. 2013 Apr; 138(2):549-59. PMID: 23430224; PMCID: PMC3608871.
    13. Wang S, Huang J, Lyu H, Cai B, Yang X, Li F, Tan J, Edgerton SM, Thor AD, Lee CK, Liu B. Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer. Breast Cancer Res. 2013; 15(5):R101. PMID: 24168763; PMCID: PMC3978722.
    14. Tophkhane C, Yang SH, Jiang Y, Ma Z, Subramaniam D, Anant S, Yogosawa S, Sakai T, Liu WG, Edgerton S, Thor A, Yang X. p53 inactivation upregulates p73 expression through E2F-1 mediated transcription. PLoS One. 2012; 7(8):e43564. PMID: 22952705; PMCID: PMC3431388.
    15. Kabos P, Finlay-Schultz J, Li C, Kline E, Finlayson C, Wisell J, Manuel CA, Edgerton SM, Harrell JC, Elias A, Sartorius CA. Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures. Breast Cancer Res Treat. 2012 Sep; 135(2):415-32. PMID: 22821401; PMCID: PMC3818141.
    16. Deng XS, Wang S, Deng A, Liu B, Edgerton SM, Lind SE, Wahdan-Alaswad R, Thor AD. Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers. Cell Cycle. 2012 Jan 15; 11(2):367-76. PMID: 22189713.
      View in: PubMed
    17. Liu B, Fan Z, Edgerton SM, Yang X, Lind SE, Thor AD. Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions. Cell Cycle. 2011 Sep 01; 10(17):2959-66. PMID: 21862872.
      View in: PubMed
    18. Lara JF, Thor AD, Dressler LG, Broadwater G, Bleiweiss IJ, Edgerton S, Cowan D, Goldstein LJ, Martino S, Ingle JN, Henderson IC, Norton L, Winer EP, Hudis CA, Ellis MJ, Berry DA, Hayes DF. p53 Expression in node-positive breast cancer patients: results from the Cancer and Leukemia Group B 9344 Trial (159905). Clin Cancer Res. 2011 Aug 01; 17(15):5170-8. PMID: 21693655; PMCID: PMC3149770.
    19. Cittelly DM, Das PM, Spoelstra NS, Edgerton SM, Richer JK, Thor AD, Jones FE. Downregulation of miR-342 is associated with tamoxifen resistant breast tumors. Mol Cancer. 2010 Dec 20; 9:317. PMID: 21172025; PMCID: PMC3024251.
    20. Das PM, Thor AD, Edgerton SM, Barry SK, Chen DF, Jones FE. Reactivation of epigenetically silenced HER4/ERBB4 results in apoptosis of breast tumor cells. Oncogene. 2010 Sep 16; 29(37):5214-9. PMID: 20603612; PMCID: PMC3007096.
    21. Yang X, Yang S, McKimmey C, Liu B, Edgerton SM, Bales W, Archer LT, Thor AD. Genistein induces enhanced growth promotion in ER-positive/erbB-2-overexpressing breast cancers by ER-erbB-2 cross talk and p27/kip1 downregulation. Carcinogenesis. 2010 Apr; 31(4):695-702. PMID: 20067990.
      View in: PubMed
    22. Liu B, Ordonez-Ercan D, Fan Z, Huang X, Edgerton SM, Yang X, Thor AD. Estrogenic promotion of ErbB2 tyrosine kinase activity in mammary tumor cells requires activation of ErbB3 signaling. Mol Cancer Res. 2009 Nov; 7(11):1882-92. PMID: 19861407.
      View in: PubMed
    23. Thor AD, Edgerton SM, Jones FE. Subcellular localization of the HER4 intracellular domain, 4ICD, identifies distinct prognostic outcomes for breast cancer patients. Am J Pathol. 2009 Nov; 175(5):1802-9. PMID: 19808643; PMCID: PMC2774046.
    24. Liu B, Fan Z, Edgerton SM, Deng XS, Alimova IN, Lind SE, Thor AD. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle. 2009 Jul 01; 8(13):2031-40. PMID: 19440038.
      View in: PubMed
    25. Alimova IN, Liu B, Fan Z, Edgerton SM, Dillon T, Lind SE, Thor AD. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle. 2009 Mar 15; 8(6):909-15. PMID: 19221498.
      View in: PubMed
    26. Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, Flockhart DA, Hancock B, Davidson N, Gralow J, Dickler M, Perez EA, Cobleigh M, Shenkier T, Edgerton S, Miller KD. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol. 2008 Oct 01; 26(28):4672-8. PMID: 18824714; PMCID: PMC2653128.
    27. Naresh A, Thor AD, Edgerton SM, Torkko KC, Kumar R, Jones FE. The HER4/4ICD estrogen receptor coactivator and BH3-only protein is an effector of tamoxifen-induced apoptosis. Cancer Res. 2008 Aug 01; 68(15):6387-95. PMID: 18676864; PMCID: PMC2538429.
    28. DiGiovanna MP, Stern DF, Edgerton S, Broadwater G, Dressler LG, Budman DR, Henderson IC, Norton L, Liu ET, Muss HB, Berry DA, Hayes DF, Thor AD. Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B. J Clin Oncol. 2008 May 10; 26(14):2364-72. PMID: 18390970.
      View in: PubMed
    29. Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, Cowan D, Broadwater G, Goldstein LJ, Martino S, Ingle JN, Henderson IC, Norton L, Winer EP, Hudis CA, Ellis MJ, Berry DA. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med. 2007 Oct 11; 357(15):1496-506. PMID: 17928597.
      View in: PubMed
    30. Liu B, Ordonez-Ercan D, Fan Z, Edgerton SM, Yang X, Thor AD. Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells. Int J Cancer. 2007 May 01; 120(9):1874-82. PMID: 17266042.
      View in: PubMed
    31. Yang S, Thor AD, Edgerton S, Yang X. Caspase-3 mediated feedback activation of apical caspases in doxorubicin and TNF-alpha induced apoptosis. Apoptosis. 2006 Nov; 11(11):1987-97. PMID: 17013758.
      View in: PubMed
    32. Kim A, Liu B, Ordonez-Ercan D, Alvarez KM, Jones LD, McKimmey C, Edgerton SM, Yang X, Thor AD. Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells. Breast Cancer Res. 2005; 7(5):R708-18. PMID: 16168116; PMCID: PMC1242139.
    33. Yang XH, Edgerton S, Thor AD. Reconstitution of caspase-3 sensitizes MCF-7 breast cancer cells to radiation therapy. Int J Oncol. 2005 Jun; 26(6):1675-80. PMID: 15870885.
      View in: PubMed
    34. DiGiovanna MP, Stern DF, Edgerton SM, Whalen SG, Moore D, Thor AD. Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. J Clin Oncol. 2005 Feb 20; 23(6):1152-60. PMID: 15718311.
      View in: PubMed
    35. Liu B, Edgerton S, Yang X, Kim A, Ordonez-Ercan D, Mason T, Alvarez K, McKimmey C, Liu N, Thor A. Low-dose dietary phytoestrogen abrogates tamoxifen-associated mammary tumor prevention. Cancer Res. 2005 Feb 01; 65(3):879-86. PMID: 15705886.
      View in: PubMed
    36. Kamath RV, Thor AD, Wang C, Edgerton SM, Slusarczyk A, Leary DJ, Wang J, Wiley EL, Jovanovic B, Wu Q, Nayar R, Kovarik P, Shi F, Huang S. Perinucleolar compartment prevalence has an independent prognostic value for breast cancer. Cancer Res. 2005 Jan 01; 65(1):246-53. PMID: 15665301.
      View in: PubMed
    37. Kosanke S, Edgerton SM, Moore D, Yang X, Mason T, Alvarez K, Jones L, Kim A, Thor AD. Mammary tumor heterogeneity in wt-ErbB-2 transgenic mice. Comp Med. 2004 Jun; 54(3):280-7. PMID: 15253274.
      View in: PubMed
    38. Tedesco KL, Thor AD, Johnson DH, Shyr Y, Blum KA, Goldstein LJ, Gradishar WJ, Nicholson BP, Merkel DE, Murrey D, Edgerton S, Sledge GW. Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial. J Clin Oncol. 2004 Mar 15; 22(6):1071-7. PMID: 15020608.
      View in: PubMed
    39. Edgerton SM, Moore D, Merkel D, Thor AD. erbB-2 (HER-2) and breast cancer progression. Appl Immunohistochem Mol Morphol. 2003 Sep; 11(3):214-21. PMID: 12966347.
      View in: PubMed
    40. Yang X, Edgerton SM, Kosanke SD, Mason TL, Alvarez KM, Liu N, Chatterton RT, Liu B, Wang Q, Kim A, Murthy S, Thor AD. Hormonal and dietary modulation of mammary carcinogenesis in mouse mammary tumor virus-c-erbB-2 transgenic mice. Cancer Res. 2003 May 15; 63(10):2425-33. PMID: 12750262.
      View in: PubMed
    41. Jeruss JS, Liu NX, Chung Y, Magrane G, Waldman F, Edgerton S, Yang X, Thor AD. Characterization and chromosomal instability of novel derived cell lines from a wt-erbB-2 transgenic mouse model. Carcinogenesis. 2003 Apr; 24(4):659-64. PMID: 12727793.
      View in: PubMed
    42. Eppenberger-Castori S, Moore DH, Thor AD, Edgerton SM, Kueng W, Eppenberger U, Benz CC. Age-associated biomarker profiles of human breast cancer. Int J Biochem Cell Biol. 2002 Nov; 34(11):1318-30. PMID: 12200028.
      View in: PubMed
    43. Thor AD, Eng C, Devries S, Paterakos M, Watkin WG, Edgerton S, Moore DH, Etzell J, Waldman FM. Invasive micropapillary carcinoma of the breast is associated with chromosome 8 abnormalities detected by comparative genomic hybridization. Hum Pathol. 2002 Jun; 33(6):628-31. PMID: 12152162.
      View in: PubMed
    44. Thor AD, Edgerton SM, Liu S, Moore DH, Kwiatkowski DJ. Gelsolin as a negative prognostic factor and effector of motility in erbB-2-positive epidermal growth factor receptor-positive breast cancers. Clin Cancer Res. 2001 Aug; 7(8):2415-24. PMID: 11489821.
      View in: PubMed
    45. Liu S, Edgerton SM, Moore DH, Thor AD. Measures of cell turnover (proliferation and apoptosis) and their association with survival in breast cancer. Clin Cancer Res. 2001 Jun; 7(6):1716-23. PMID: 11410511.
      View in: PubMed
    46. Thor AD, Liu S, Edgerton S, Moore D, Kasowitz KM, Benz CC, Stern DF, DiGiovanna MP. Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer. J Clin Oncol. 2000 Sep 15; 18(18):3230-9. PMID: 10986055.
      View in: PubMed
    47. Thor AD, Liu S, Moore DH, Shi Q, Edgerton SM. p(21WAF1/CIP1) expression in breast cancers: associations with p53 and outcome. Breast Cancer Res Treat. 2000 May; 61(1):33-43. PMID: 10930088.
      View in: PubMed
    48. Paterakos M, Watkin WG, Edgerton SM, Moore DH, Thor AD. Invasive micropapillary carcinoma of the breast: a prognostic study. Hum Pathol. 1999 Dec; 30(12):1459-63. PMID: 10667424.
      View in: PubMed
    49. Thor AD, Liu S, Moore DH, Edgerton SM. Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast cancer. J Clin Oncol. 1999 Feb; 17(2):470-7. PMID: 10080587.
      View in: PubMed
    50. Thor AD, Berry DA, Budman DR, Muss HB, Kute T, Henderson IC, Barcos M, Cirrincione C, Edgerton S, Allred C, Norton L, Liu ET. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst. 1998 Sep 16; 90(18):1346-60. PMID: 9747866.
      View in: PubMed
    51. Breuer B, Smith S, Thor A, Edgerton S, Osborne MP, Minick R, Cody HS, Nowak E, Cortese A, Simmons RM, Carney WP, Brandt-Rauf PW. ErbB-2 protein in sera and tumors of breast cancer patients. Breast Cancer Res Treat. 1998 Jun; 49(3):261-70. PMID: 9776510.
      View in: PubMed
    52. Passik SD, Dugan W, McDonald MV, Rosenfeld B, Theobald DE, Edgerton S. Oncologists' recognition of depression in their patients with cancer. J Clin Oncol. 1998 Apr; 16(4):1594-600. PMID: 9552071.
      View in: PubMed
    53. Benz CC, O'Hagan RC, Richter B, Scott GK, Chang CH, Xiong X, Chew K, Ljung BM, Edgerton S, Thor A, Hassell JA. HER2/Neu and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancer. Oncogene. 1997 Sep 25; 15(13):1513-25. PMID: 9380403.
      View in: PubMed
    54. Krajewski S, Thor AD, Edgerton SM, Moore DH, Krajewska M, Reed JC. Analysis of Bax and Bcl-2 expression in p53-immunopositive breast cancers. Clin Cancer Res. 1997 Feb; 3(2):199-208. PMID: 9815673.
      View in: PubMed
    55. Millikan R, Hulka B, Thor A, Zhang Y, Edgerton S, Zhang X, Pei H, He M, Wold L, Melton LJ, et al. p53 mutations in benign breast tissue. J Clin Oncol. 1995 Sep; 13(9):2293-300. PMID: 7666086.
      View in: PubMed
    56. Axelsson K, Ljung BM, Moore DH, Thor AD, Chew KL, Edgerton SM, Smith HS, Mayall BH. Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. J Natl Cancer Inst. 1995 Jul 05; 87(13):997-1008. PMID: 7543156.
      View in: PubMed
    57. Eng Tan P, Benz CC, Dollbaum C, Moore DH, Edgerton SM, Zava DT, Thor AD. Prognostic value of Cathepsin D expression in breast cancer: immunohistochemical assessment and correlation with radiometric assay. Ann Oncol. 1994 Apr; 5(4):329-36. PMID: 8075029.
      View in: PubMed
    58. Kupryjanczyk J, Thor AD, Beauchamp R, Merritt V, Edgerton SM, Bell DA, Yandell DW. p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci U S A. 1993 Jun 01; 90(11):4961-5. PMID: 8506342; PMCID: PMC46633.
    59. Koerner FC, Goldberg DE, Edgerton SM, Schwartz LH. pS2 protein and steroid hormone receptors in invasive breast carcinomas. Int J Cancer. 1992 Sep 09; 52(2):183-8. PMID: 1521907.
      View in: PubMed
    60. Thor AD, Moore DH II, Edgerton SM, Kawasaki ES, Reihsaus E, Lynch HT, Marcus JN, Schwartz L, Chen LC, Mayall BH, et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst. 1992 Jun 03; 84(11):845-55. PMID: 1317462.
      View in: PubMed
    61. Thor AD, Koerner FC, Edgerton SM, Wood WC, Stracher MA, Schwartz LH. pS2 expression in primary breast carcinomas: relationship to clinical and histological features and survival. Breast Cancer Res Treat. 1992; 21(2):111-9. PMID: 1627814.
      View in: PubMed
    62. Thor A, Benz C, Moore D, Goldman E, Edgerton S, Landry J, Schwartz L, Mayall B, Hickey E, Weber LA. Stress response protein (srp-27) determination in primary human breast carcinomas: clinical, histologic, and prognostic correlations. J Natl Cancer Inst. 1991 Feb 06; 83(3):170-8. PMID: 1988702.
      View in: PubMed
    63. Schwartz LH, Koerner FC, Edgerton SM, Sawicka JM, Rio MC, Bellocq JP, Chambon P, Thor AD. pS2 expression and response to hormonal therapy in patients with advanced breast cancer. Cancer Res. 1991 Jan 15; 51(2):624-8. PMID: 1985778.
      View in: PubMed
    64. Louis DN, Edgerton S, Thor AD, Hedley-Whyte ET. Proliferating cell nuclear antigen and Ki-67 immunohistochemistry in brain tumors: a comparative study. Acta Neuropathol. 1991; 81(6):675-9. PMID: 1679278.
      View in: PubMed
    65. Lloveras B, Edgerton S, Thor AD. Evaluation of in vitro bromodeoxyuridine labeling of breast carcinomas with the use of a commercial kit. Am J Clin Pathol. 1991 Jan; 95(1):41-7. PMID: 1987751.
      View in: PubMed
    66. Thor AD, Schwartz LH, Koerner FC, Edgerton SM, Skates SJ, Yin S, McKenzie SJ, Panicali DL, Marks PJ, Fingert HJ, et al. Analysis of c-erbB-2 expression in breast carcinomas with clinical follow-up. Cancer Res. 1989 Dec 15; 49(24 Pt 1):7147-52. PMID: 2573426.
      View in: PubMed
    67. Thor AD, Edgerton SM. Monoclonal antibodies reactive with human breast or ovarian carcinoma: in vivo applications. Semin Nucl Med. 1989 Oct; 19(4):295-308. PMID: 2678481.
      View in: PubMed
    Edgerton's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _

    Copyright © 2017 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.10.0)